Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530 is registered in ClinicalTrials.gov with Aura Biosciences as lead sponsor.

NCT NCT04417530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04417530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Lead sponsor
Aura Biosciences
Phase
Phase 2
Overall status
Completed
Start date
August 5, 2020
Completion date
April 22, 2024
Enrollment
22 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal melanoma, ocular melanoma, uveal melanoma